vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Amarin Corp plc (AMRN). Click either name above to swap in a different company.
Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $44.9M, roughly 1.0× AbCellera Biologics Inc.). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -23.3%, a 3.3% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 7.0%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -18.3%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
ABCL vs AMRN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $45.1M |
| Net Profit | $-8.9M | $-10.5M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | 35.5% |
| Net Margin | -19.9% | -23.3% |
| Revenue YoY | 788.4% | 7.0% |
| Net Profit YoY | 73.9% | 33.0% |
| EPS (diluted) | $-0.03 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $45.1M | ||
| Q4 25 | $44.9M | $49.2M | ||
| Q3 25 | $9.0M | $49.7M | ||
| Q2 25 | $17.1M | $72.7M | ||
| Q1 25 | $4.2M | $42.0M | ||
| Q4 24 | $5.0M | $62.3M | ||
| Q3 24 | $6.5M | $42.3M | ||
| Q2 24 | $7.3M | $67.5M |
| Q1 26 | — | $-10.5M | ||
| Q4 25 | $-8.9M | $-1.2M | ||
| Q3 25 | $-57.1M | $-7.7M | ||
| Q2 25 | $-34.7M | $-14.1M | ||
| Q1 25 | $-45.6M | $-15.7M | ||
| Q4 24 | — | $-48.6M | ||
| Q3 24 | $-51.1M | $-25.1M | ||
| Q2 24 | $-36.9M | $1.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 44.7% | ||
| Q2 25 | — | 69.2% | ||
| Q1 25 | — | 59.8% | ||
| Q4 24 | — | -15.4% | ||
| Q3 24 | — | 38.5% | ||
| Q2 24 | — | 63.4% |
| Q1 26 | — | 35.5% | ||
| Q4 25 | -63.7% | -12.9% | ||
| Q3 25 | -851.8% | -22.4% | ||
| Q2 25 | -290.2% | -22.0% | ||
| Q1 25 | -1479.6% | -39.9% | ||
| Q4 24 | — | -84.3% | ||
| Q3 24 | -1439.4% | -59.5% | ||
| Q2 24 | -1276.2% | -0.8% |
| Q1 26 | — | -23.3% | ||
| Q4 25 | -19.9% | -2.5% | ||
| Q3 25 | -637.8% | -15.6% | ||
| Q2 25 | -203.3% | -19.4% | ||
| Q1 25 | -1077.2% | -37.4% | ||
| Q4 24 | — | -78.0% | ||
| Q3 24 | -785.4% | -59.4% | ||
| Q2 24 | -504.3% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.03 | $0.00 | ||
| Q3 25 | $-0.19 | $-0.02 | ||
| Q2 25 | $-0.12 | $-0.03 | ||
| Q1 25 | $-0.15 | $-0.04 | ||
| Q4 24 | — | $-0.12 | ||
| Q3 24 | $-0.17 | $-0.06 | ||
| Q2 24 | $-0.13 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $307.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | — |
| Total Assets | $1.4B | $645.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $307.8M | ||
| Q4 25 | $128.5M | $302.6M | ||
| Q3 25 | $83.2M | $286.6M | ||
| Q2 25 | $92.4M | $298.7M | ||
| Q1 25 | $159.3M | $281.8M | ||
| Q4 24 | $156.3M | $294.2M | ||
| Q3 24 | $126.6M | $305.7M | ||
| Q2 24 | $148.3M | $306.7M |
| Q1 26 | — | — | ||
| Q4 25 | $966.9M | $459.3M | ||
| Q3 25 | $964.0M | $458.9M | ||
| Q2 25 | $1.0B | $464.9M | ||
| Q1 25 | $1.0B | $473.7M | ||
| Q4 24 | $1.1B | $486.2M | ||
| Q3 24 | $1.1B | $531.4M | ||
| Q2 24 | $1.1B | $551.9M |
| Q1 26 | — | $645.8M | ||
| Q4 25 | $1.4B | $670.8M | ||
| Q3 25 | $1.4B | $659.8M | ||
| Q2 25 | $1.4B | $670.1M | ||
| Q1 25 | $1.3B | $655.7M | ||
| Q4 24 | $1.4B | $685.3M | ||
| Q3 24 | $1.4B | $750.6M | ||
| Q2 24 | $1.4B | $799.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | — |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.7M | $15.3M | ||
| Q3 25 | $-52.6M | $-12.7M | ||
| Q2 25 | $-32.4M | $16.6M | ||
| Q1 25 | $-11.6M | $-12.5M | ||
| Q4 24 | $-108.6M | $-13.3M | ||
| Q3 24 | $-28.9M | $-2.4M | ||
| Q2 24 | $-30.0M | $-2.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | — | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | — | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | — | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.81× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
